cyclohexanol has been researched along with Huntington Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonelli, RM; Holl, AK; Holl, EM; Painold, A; Wilkinson, L | 1 |
| de Miguel, R; De Petrocellis, L; Di Marzo, V; Fernández-Ruiz, J; Lastres-Becker, I; Makriyannis, A | 1 |
| Dunbar, GL; Lescaudron, L; Rossignol, J; Sandstrom, MI | 1 |
| Boersen, AJ; Bombard, MC; Dey, ND; Dunbar, GL; Hulce, VD; Lescaudron, L; Lu, M; Myers, RA; Sandstrom, MI; York, LR | 1 |
| Dragunow, M; Faull, RL; Glass, M | 1 |
1 review(s) available for cyclohexanol and Huntington Disease
| Article | Year |
|---|---|
Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: use of gangliosides, substituted pyrimidines, and mesenchymal stem cells.
Topics: Animals; Behavior, Animal; Brain; Cyclohexanols; Disease Models, Animal; Gangliosides; Humans; Huntington Disease; Mesoderm; Mice; Nerve Growth Factors; Neuroprotective Agents; Pluripotent Stem Cells; Pyrimidines; Stem Cell Transplantation; Up-Regulation | 2006 |
1 trial(s) available for cyclohexanol and Huntington Disease
| Article | Year |
|---|---|
Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Huntington Disease; Irritable Mood; Male; Middle Aged; Nausea; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
3 other study(ies) available for cyclohexanol and Huntington Disease
| Article | Year |
|---|---|
Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amino Acids, Neutral; Animals; Arachidonic Acids; Basal Ganglia; Cannabinoid Receptor Modulators; Capsaicin; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Dopamine; Endocannabinoids; gamma-Aminobutyric Acid; Huntington Disease; Hyperkinesis; Male; Motor Activity; Nitro Compounds; Palmitates; Piperidines; Propionates; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Cannabinoid; Receptors, Drug; Rimonabant | 2003 |
The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease.
Topics: Age Factors; Analysis of Variance; Animals; Behavior, Animal; Brain; Cyclohexanols; Disease Models, Animal; Exploratory Behavior; Female; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; Motor Skills; Movement Disorders; Mutation; Pyrimidines; Reaction Time | 2007 |
Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
Topics: Aged; Aged, 80 and over; Autoradiography; Cannabinoids; Cyclohexanols; Humans; Huntington Disease; In Vitro Techniques; Male; Middle Aged; Presynaptic Terminals; Receptors, Cannabinoid; Receptors, Drug; Substantia Nigra | 1993 |